Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Online ahead of print]

Impact of Screening on Cervical Cancer Incidence: A Population-Based Case-Control Study in the United States

Affiliations

Impact of Screening on Cervical Cancer Incidence: A Population-Based Case-Control Study in the United States

Rebecca Landy et al. Int J Cancer.

Abstract

Cervical cancer is widely preventable through screening, but little is known about the duration of protection offered by a negative screen in North America. A case-control study was conducted with records from population-based registries in New Mexico. Cases were women diagnosed with cervical cancer in 2006-2016, obtained from the Tumor Registry. Five controls per case from the New Mexico HPV Pap Registry were matched to cases by sex, age and place of residence. Dates and results of all cervical screening and diagnostic tests since 2006 were identified from the pap registry. We estimated the odds ratio of nonlocalized (Stage II+) and localized (Stage I) cervical cancer associated with attending screening in the 3 years prior to case-diagnosis compared to women not screened in 5 years. Of 876 cases, 527 were aged 25-64 years with ≥3 years of potential screening data. Only 38% of cases and 61% of controls attended screening in a 3-year period. Women screened in the 3 years prior to diagnosis had 83% lower risk of nonlocalized cancer (odds ratio [OR] = 0.17, 95% CI: 0.12-0.24) and 48% lower odds of localized cancer (OR = 0.52, 95% CI: 0.38-0.72), compared to women not screened in the 5 years prior to diagnosis. Women remained at low risk of nonlocalized cancer for 3.5-5 years after a negative screen compared to women with no negative screens in the 5 years prior to diagnosis. Routine cervical screening is effective at preventing localized and nonlocalized cervical cancers; 3 yearly screening prevents 83% of nonlocalized cancers, with no additional benefit of more frequent screening. Increasing screening coverage remains essential to further reduce cervical cancer incidence.

Keywords: HPV; cancer registry; cancer screening; case-control; cervical cancer; cervical screening; cytology; pap smear.

Similar articles

See all similar articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
    1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
    1. Moyer VA. Screening for cervical cancer: US preventive services task force recommendation statement. Ann Intern Med 2012;156:880-91.
    1. US Preventive Services Task Force. Screening for cervical cancer US preventive services task force recommendation statement. JAMA 2018;320:674-86.
    1. U.S. Food & Drug Administration. Gardasil Vaccine Safety. Silver Spring, MD: US FDA, 2018. 2009.

LinkOut - more resources

Feedback